Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd. (Enlivex) covers the month of May 2020, specifically dated May 19, 2020. The filing announces the scheduling of the Company's 2020 Annual and Extraordinary General Meeting of Shareholders to be held on June 24, 2020, at its principal executive offices in Nes Ziona, Israel. The filing also details immediate changes to the composition of the Board of Directors' committees.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder meeting logistics rather than financial performance.
Material Changes
- Board Committee Reshuffle: Executive Chairman Shai Novik voluntarily stepped down from the Audit Committee and the Compensation Committee effective May 19, 2020, though he remains a member of the Board.
- New Appointments: Michel Habib was appointed to the Audit Committee, and Dr. Bernhard Kirschbaum was appointed to the Compensation Committee, both effective immediately.
- Committee Composition: The Audit Committee now consists of Michel Habib, Dr. Avri Havron (Chair), and Dr. Gili Hart. The Compensation Committee now consists of Dr. Bernhard Kirschbaum, Dr. Avri Havron, and Dr. Gili Hart (Chair).
- Independence Determination: The Board affirmed the independence of six directors: Michel Habib, Dr. Avri Havron, Dr. Gili Hart, Dr. Bernhard Kirschbaum, Mr. Sangwoo Lee, and Dr. Hyun Gyu Lee.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors. It notes that Mr. Novik's departure from the committees is in light of a proposed amendment to his agreement with the Company, which is described in Proposal Two of the attached Proxy Statement. The filing incorporates the Proxy Statement and Proxy Card by reference.
Key Facts for Investor Verification
- Verify the details of the proposed amendment to Executive Chairman Shai Novik's agreement referenced in Proposal Two of the Proxy Statement.
- Confirm the voting procedures and agenda for the Annual and Extraordinary General Meeting scheduled for June 24, 2020.
- Review the attached Proxy Statement (Exhibit 99.1) for full context regarding the board changes and shareholder proposals.